Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 4, 1996, Pages 335-342

  Veerman, Gijsbert ^a   Ruiz Van Haperen, Veronique W T ^a,b   Vermorken, Jan B ^a   Noordhuis, Paul ^a   Braakhuis, Boudewijn J M ^a   Pinedo, Herbert M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colon cancer; Continuous infusion; Gemcitabine; Schedule dependence

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; COLON TUMOR; DRUG ADMINISTRATION; DRUG SCREENING; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MOUSE; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; COLON CANCER; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; INFUSIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 0029666336     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050492     Document Type: Article

References (32)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 8 : 1535
2. Ackland SP, Schilsky RL (1987) High dose methotrexate: a critical reappraisal. J Clin Oncol 5 : 2017
3. Anderson H, Thatcher N, Walling J, Hansen H, Mejdal P (1994) A phase I study of 24 hour infusion of gemcitabine in patients with previously untreated, locally advanced, non-small cell lung cancer (abstract 1164). Proc Am Soc Clin Oncol 13 : 348
4. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between ciplatin and gemcitabine in vitro. Clin Cancer Res 2 : 521
5. Boven E, Schipper H, Erkelens CAM, Hatty SA, Pinedo HM (1993) The influence of the schedule and the dose of gemcitabine on the anti-tumor efficacy in experimental human cancer. Br J Cancer 68 : 52
6. Braakhuis BJM, Van Dongen GAMS, Vermorken JB, Snow GB (1991) Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51 : 211
7. Braakhuis BJM, Jansen G, Noordhuis P, Kegel A, Peters GJ (1993) Importance of pharmacokinetics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol 46 : 2155
8. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ (1995) Schedule dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 22 [Suppl 11] : 42
9. Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16 : 215
10. Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W (1991) Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27 : 258
11. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W (1992) Gemicitabine in leukemia: a phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 10 : 406
12. Heinemann V, Jehn U (1990) Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. Leukemia 4 : 790
13. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50 : 4417
14. Kaye SB (1994) Gemcitabine: current status of phase I and II trials. J Clin Oncol 8 : 1527
15. Klohs WD, Steinkampf RW (1988) Possible link between the intrinsic drug resistance of colon tumours and a detoxification mechanism of intestinal cells. Cancer Res 48 : 3025
16. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JGA (1989) Prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7 : 425
17. Lund B, Kristjansen PEG, Hansen H (1993) Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19 : 45
18. Olsen EA, Durham MD (1991) The pharmacology of methotrexate. J Am Acad Dermatol 25 : 306
19. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Braakhuis BJM (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22 [suppl 11] : 72
20. Peters GJ, Van Dijk J, Nadal JC, Van Groeningen CJ, Lankelma J, Pinedo HM (1987) Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1 : 113
21. Peters GJ, Kraal I, Pinedo HM (1992) In vitro and in vivo studies on the combination of brequinar sodium (DUP 785; NSC 368390) with 5-fluorouracil; effects of uridine. Br J Cancer 65 : 229
22. Peters GJ, Schornagel JH, Milano GA (1993) Clinical pharmacokinetics of antimetabolites. Cancer Surv 17 : 123
23. Pinkel D (1993) Intravenous mercaptopurine: life begins at 40. J Clin Oncol 11 : 1826
24. Plunkett W, Gandhi V (1992) Pharmacokinetics of arabinosyl cytosine. J Infus Chemother 2 : 169
25. Ruiz van Haperen VWT, Veerman G, Braakhuis BJM, Vermorken JB, Boven E, Leyva A, Peters GJ (1993) Deoxycytidine kinase and deoxycytidinedeaminase activities in human tumour xenografts. Eur J Cancer 29A : 2132
26. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ (1994) Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 48 : 1327
27. Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB (1993) Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5 : 223
28. Tobias JS (1992) Current role of chemotherapy in head and neck cancer. Drugs 43 : 333
29. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24 : 148
30. Van Ark-Otte J, Peters GJ, Pizao PE, Keepers YPAM, Giaccone G (1994) In vitro schedule dependency of E09 and miltefosine in comparison to standard drugs in colon cancer cells. Int J Oncol 4 : 709
31. Van Laar JAM, Rustum YM, Van der Wilt CL, Smid K, Kuiper CM, Pinedo HM, Peters GJ (1996) Tumor size and origin determine antitumor activity of cisplatin or 5-Fluorouracil and its modulation by leucovorin in murine colon carcinomas. Cancer Chemother Pharmacol (in press).
32. 18F] -5-fluorouracil in a mouse bearing two colon tumours with a different 5-fluorouracil sensitivity. A study for a correlation with oncological results. Nucl Med Biol (in press)